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Purpose. Previously, we have shown that the amphiphilic oligopeptide SA2 (Ac-Ala-Ala-Val-Val-Leu-
Leu-Leu-Trp-Glu-Glu-COOH) spontaneously self-assemble into nano-sized vesicles in aqueous environ-
ment. Relative weak individual intermolecular interactions dominate such oligopeptide assemblies. In
this study we aimed at improving the stability of such peptide vesicles by covalently crosslinking the
oligopeptide vesicles using disulﬁde bonds. Two and three cysteines were introduced in the SA2 peptide
sequence to allow crosslinking (Ac-Ala-Cys-Val-Cys-Leu-(Leu/Cys)-Leu-Trp-Glu-Glu-COOH).
Results. Upon disulﬁde formation the crosslinked vesicles remained stable under conditions that
disrupted the non-crosslinked peptide vesicles. The stabilized vesicles were more closely examined in
terms of particle size (distribution) using atomic force microscopy, cryogenic electron microscopy, as well
as dynamic light scattering analysis, showing an average particle radius in number between 15 and 20 nm.
Using entrapment of calcein it was shown that intermolecular crosslinking of peptides within the vesicles
did not affect the permeability for calcein.
Conclusion. Introduction of cysteines into the hydrophobic domain of the SA2 amphiphilic oligopeptides
is a feasible strategy for crosslinking the peptide vesicles. Such small crosslinked oligopeptide vesicles
may hold promise for drug delivery applications.
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INTRODUCTION
Self-assembly of peptides can result in a whole array of
different supramolecular morphologies (1–6). Long polypep-
tides as well as oligopeptides have been exploited to develop
hydrogels, nanoribbons, or peptide sheets, several of these
new (bio)materials displaying unique and useful macromo-
lecular characteristics (7–9). Previously, we developed amphi-
philic oligopeptides that assemble into nanosized vesicles
(10). These peptides display a conical design, in which the
amino acids that constitute the hydrophobic domain increase
in size towards the hydrophilic part, while charged amino
acids function as the hydrophilic domain (e.g. Ac-Ala-Ala-
Val-Val-Leu-Leu-Leu-Trp-Glu-Glu; SA2). Nano-vesicles
formed spontaneously upon hydration of these peptides and
could be reversibly disrupted and re-assembled upon changes
in environmental factors like pH (9).
The individual intermolecular interactions that stabilize
these oligopeptide vesicles, like hydrophobic interactions, van
der Waals forces, and hydrogen bonding, are relatively weak.
The supramolecular structure exists in equilibrium with
oligopeptides in free form, displaying a critical aggregation
concentration (CAC) of around 0.5 μM for the SA2 peptide
(10,11). As a consequence, the supramolecular peptide
assemblies destabilize upon dilution, and for some applica-
tions of these peptide vesicles a structure that is more stable
may be desired. For example, in the case of drug delivery
application, injection into the bloodstream or tissue may
destabilize the peptide assemblies by binding of the free
peptides to blood components or by extensive dilution of the
assemblies.
Hence, in this study we aimed at stabilizing the pre-
viously developed oligopeptide vesicles. We used intermolec-
ular disulﬁde formation, which is controllable as well as stable
in aqueous environment, introducing two and three cysteines
into the hydrophobic domain of the oligopeptide sequence.
MATERIALS & METHODS
Materials
Chemicals were from Sigma (St. Louis, USA) unless
indicated otherwise. Hepes, acetic anhydride was from Fluka,
Ellman’s reagent was from Pierce (Rockford, USA). pET
SUMO and chemically competent TOP10 and BL21(DE3) E.
coli cells were from Invitrogen (Carlsbad, USA). SUMO
protease was from (LifeSensors, Malvern, USA).
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Two sets of complementary oligo DNA (5′ GCGTGCG
TGTGTCTGCTGCTGTGGGAAGAATGAGGATCCA 3′;5 ′ GGATCCT
CATTCTTCCCACAGCAGCAGACACACGCACGCA 3′ and GCGTG
CGTGTGTCTGTGCCTGTGGGAAGAATGAGGATCCA 3′;5 ′ GGATCCT
CATTCTTCCCACAGGCACAGACACACGCACGCA 3′)w e r e
designed to have 3′ A-overhangs for directional ligation
(TA cloning) and a BamHI recognition site after the peptide
coding region and stop codon. Both complementary oligos
were annealed at a 5.0 μM DNA concentration using
temperature gradients (cooling at 0.2° per second; 10 min
95°C, cooling to 30°C, 10 min 75°C, cooling to 30°C, 10 min
65°C, cooling to 30°C) and ligated into pET SUMO with T4
DNA ligase (Fermentas, Burlington, USA). After transfor-
mation of TOP10 E. Coli cells, colonies were screened for the
right DNA construct by colony PCR and subsequent BamHI
(Fermentas, Burlington, USA) restriction analysis on puriﬁed
plasmid DNA. Correct insertion of the dsDNAwas conﬁrmed
by DNA sequencing (BaseClear, Leiden, The Netherlands).
Peptide Biosynthesis
E. Coli BL21(DE3) cells were transformed with plasmids
encoding the SUMO-peptide fusion protein, and expression
and protein puriﬁcation were performed as described before
(10). Brieﬂy, bacteria were cultured in a 5 L Luria Broth pO2-
stat fed-batch fermentation. Protein expression was induced
by addition of isopropyl-β-D-thiogalactopyranoside (IPTG)
(Fisher Emergo, Landsmeer, The Netherlands) to a ﬁnal
concentration of 1.0 mM. After 3 h, cells were harvested by
centrifugation for 15 min at 3,500 g and lysed by means of a
single freeze-thaw step and passing twice through an Avestin
C5 cell-cracker (ATA Scientiﬁc, Lucas Heights, Australia).
The cleared lysate, the His-tagged fusion protein was puriﬁed
on a 20 ml HisTrap column (GE Healthcare, Upsala,
Sweden) by automated ﬂow puriﬁcation. After elution with
a 300 mM phosphate buffer (pH 8.0) containing 400 mM
imidazole and buffer exchange to Hepes buffered saline
(HBS, 20 mM Hepes, 150 mM NaCl, pH 8.0) supplemented
with 2.5 mM dithiotreitol (DTT), the peptides were cleaved off
the fusion protein by incubation with 2 u/ml SUMO protease at
30°C. The peptide was puriﬁed from the SUMO protein and
protease using a size exclusion column of Sephadex™ G–25
Fine material (GE Healthcare, Upsala, Sweden) in a buffer of
10 mM Hepes, 75 mM NaCl, 2.5 mM DTT, pH 8.0. Subse-
quently, N-terminally acetylation was performed for 1 h in 50%
ddH2O, 25% methanol 25% acetic anhydride (v/v). Acetyla-
tion was conﬁrmed (>95%) by determination of free amines
using 2,4,6-trinitrobenzene sulfonic acid (Pierce, Rockford,
USA) according to manufacturer’s protocol. The solvents were
removed by reduced pressure evaporation. The correct peptide
mass was conﬁrmed by mass spectrometry after S-carboxyme-
thylation of the cysteine residues by iodoacetic acid (12)
(SA2C2 expected mass 1294.1; found mass 1294.0; SA2C3
expected mass 1282.4; found mass 1281.5 (diiodoacetylated)).
Gel Electrophoresis
For sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE), samples were boiled in Laemmli
sample buffer without (non-reducing conditions) or with
25% β-mercaptoethanol (v/v) for 5 min and loaded onto a
15% acrylamide gel. Electrophoresis was performed at room
temperature, applying 10 mA per gel until the running front
reached the end of the gel. The gel was ﬁxed in a 38/50/12
(v/v/v) mixture of water/methanol/acetic acid followed by
silver staining. PageRuler prestained protein ladders were
obtained from Fermentas (Burlington, USA).
Peptide Self-assembly
The acetylated peptides were reconstituted in ddH2O
and washed as follows. Typically, 8.0 μmol of peptides were
sedimented after acidifying with HCl (pH<2.5) the peptide
solution (15 ml) by centrifugation for 30 min at 13,000 g, and
the supernatant was carefully removed. Peptide self-assembly
was performed by adding 3.0 ml of 20 mM phosphate buffer
(PB), pH 8.0 on top of the pellet, excluding mechanical input.
The peptide solutions were exposed to air for 16 h. The
peptide concentration in the dispersions was determined by
UV absorbance of the tryptophan residue at 280 nm, using a
molar extinction coefﬁcient of 5,690 l mol
−1cm
−1.T h e
measurements were checked on light scattering and, if
needed corrected for according to ref. 10 (13).
Ellman’s Reaction
To the peptide dispersions diluted in 0.1 M sodium
phosphate, 1.0 mM EDTA, pH 7.0 Ellman’s Reagent was
added, to a concentration of 71 μg/ml. The conversion to 2-
nitro-5-thiobenzoic acid was monitored at 412 nm in a
Shimadzu spectrophotometer. The conversion was considered
complete when the signal became stable over time (typically
after 16 h). Subsequently, the free thiols were quantiﬁed using
the molar extinction coefﬁcient of 2-nitro-5-thiobenzoic acid
(14 150 l mol
−1cm
−1)(14).
Dynamic Light Scattering
Dynamic light scattering measurements were performed
in a Malvern ALV CGS-3 goniometer (Malvern Instruments,
Malvern, U.K.) containing a He-Ne laser source (λ=
632.8 nm, 22 mW output power) under an angle of 90°. The
DLS time correlation was analyzed by ALV Correlator 3.0
software (ALV, Langen, Germany). The refractive indices
used were 1.333 (water) and 1.431 (DMF). In general, the
solvents used to dilute the peptides were ﬁltered through a
0.2 μm ﬁlter before use, and three independent light
scattering experiments were performed on the peptide
samples.
Electron Microscopy
Cryogenic transmission electron microscopy (TEM)
analysis was performed on 2.5 mM peptide dispersions.
Samples were applied on glow-discharged 200 mesh grids,
covered with Quantifoil holey carbon foil (Micro Tools
GmbH, Jena, Germany) and blotted for 0.5 s at 100%
relative humidity. Immediately, the samples were vitriﬁed by
plunging the grid into liquid ethane using a Vitrobot (FEI
Company, Eindhoven, The Netherlands) and subsequently
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Tecnai12 transmission electron microscope (FEI co, Eind-
hoven, The Netherlands). Samples were observed at 120 kV
with low-dose imaging conditions to avoid melting of the
vitriﬁed ﬁlm. Images were recorded on TemCam-0124 camera
(TVIPS GmBH, Gauting, Germany) and processed with
AnalySIS software.
Atomic Force Microscopy
Freshly cleaved mica was incubated for 5 min with
0.1 mg/ml poly-ornithine (30–70 kDa, Sigma, St. Louis,
USA) and subsequently washed 4 times with water. A
0.3 mM peptide dispersion was applied on the coated mica
and incubated for 5 min. The peptide dispersion was
removed, the mica was rinsed, and 10 mM PB was applied.
Tapping mode AFM was performed in aqueous environment
with a Multimode AFM and Nanoscope IIIa controller,
equipped with a Silicon Nitride NP cantilever (Veeco, Santa
Barbara, USA). A 12 μm piezoscanner (E scanner) was
employed for imaging (Veeco, Santa Barbara, USA).
Calcein Entrapment and Release Assay
Twenty ﬁve nanomol peptide was reduced in 20 mM
freshly prepared DTT for 40 min at 45°C. The peptides were
precipitated by addition of 1.0 M HCl to pH<3.0 and
centrifuged for 10 min at 13,000 g, and the pellet was washed
twice with 100 μl 10 mM HCl. Peptide self-assembly was
performed in 50 μl calcein solution (40 mg/ml calcein, 20 mM
Hepes, pH 8.0) at anaerobic conditions (degassed solution,
under argon) and subsequently exposed to air for 16 h. Size
exclusion spin columns were prepared as described by Fry et
al.( 15). Four milliliters of G25 Sephadex Medium Coarse size
(GE Healthcare, Upsala, Sweden) swollen in Hepes buffered
saline (HBS, 150 mM NaCl, 20 mM Hepes, pH 8.0) was used
per column. Fifty microliters of the peptide dispersion in
calcein solution was applied on top of the column and
centrifuged for 3 min at 350 g. The ﬂow through was collected
(fraction 1), and 50 μl of isotonic HBS were used for elution
of the subsequent fractions (7 fractions in total). Forty
microliters of each fraction were analyzed for calcein
ﬂuorescence as previously described (10). To measure
kinetics of calcein release from peptide vesicles, the void
volume fractions (1,2) were directly measured over time in a
Horiba Fluorolog ﬂuorescence spectrometer (excitation
495 nm, emission 518 nm, slits 1.0 nm). The total encapsulat-
ed calcein was quantiﬁed after reduction in 20 mM DTT and
disruption of the supramolecular structure in DMF (90%
DMF, 10% HBS). Concentration series of calcein from 1.0 µM
to 1.0 nM in 90% DMF, 10% HBS was used for calibration.
RESULTS AND DISCUSSION
Peptide Design and Production
Amphiphilic peptides that were previously shown to
assemble into vesicles were used as the basic motif to develop
crosslinkable peptide vesicles. The hydrophobic domain of
the peptide exhibits a conical shape, in which the amino acid
side groups decrease in size from the interface along its
hydrophobic chain (Table I)( 10). Considering that thiols can
function as an elegant and reversible route to stabilize the
peptide assemblies (16), two (SA2C2) or three (SA2C3)
cysteines were introduced in the hydrophobic domain
(Table I). The cysteine-containing peptides fused to the
small-ubiquitin modifying protein (SUMO) were recombi-
nantly produced in E. coli as previously described (10). SDS-
PAGE (Fig. 1) showed that the puriﬁed SUMO-SA2C2 and
SUMO-SA2C3 fusion proteins appeared around 17 kDa.
Although the expected mass of the fusion proteins (15 kDa)
is lower, the SUMO protein is known to run at a somewhat
higher apparent molecular weight on SDS-PAGE (17). The
SUMO protease speciﬁcally cleaves SUMO protein by means
of recognition of the folded SUMO protein (17). In lanes 4
and 5 (Fig. 1a) an intermediate of the cleavage process (1 h
incubation at 30°C) was analyzed on the gel, and the two
different proteins are visible: the upper band corresponds to
the SUMO-peptide fusion protein and the lower band to the
cleaved SUMO protein. Because of the small size of the
released peptide (MW 1.2 kDa), the monomeric peptide is
not visible on gel under the tested conditions. SDS-PAGE
showed that almost quantitative cleavage (>95%) was
achieved by prolongation of the incubation time to 4 h at
30°C (data not shown). Since the SUMO-peptide fusion
protein contains two (SUMO-SA2C2) or three (SUMO-
SA2C3) thiols, protein dimerization was also investigated
using SDS-PAGE under non-reducing conditions. As can be
seen in Fig. 1b, the non-cleaved fusion proteins in lanes 3
(SUMO-SA2C2) and 5 (SUMO-SA2C3) revealed the pres-
ence of protein dimers, whereas after cleavage (Figs. 1b, lanes
2 and 4) dimerization of SUMO was not observed. This is
expected since the SUMO protein itself does not contain any
cysteines.
Peptide Self-assembly and Intermolecular Crosslinking
of the Peptide Vesicles
The self-assembling capacity of acetylated SA2C2 and
SA2C3 peptides in phosphate buffer (PB) at pH 8.0 was
monitored by dynamic light scattering. Table II shows that
both peptides formed supramolecular structures with nano-
scale dimensions in PB. Using the Ellman’s free thiol assay,
formation of disulﬁde bonds within the peptide vesicles was
conﬁrmed (5% free thiol remained). The SA2C3 particle
radius (75 nm) was in good agreement with the non-cross-
linked SA2 peptide assemblies (63 nm); in the case of SA2C2
peptides a somewhat larger mean particle radius (106 nm)
was observed. To investigate whether the existence of the
observed assemblies relied on the oxidation of the cysteines,
DTT (20 mM) was added. Subsequent DLS analysis showed
that the assemblies were stable under reducing conditions,
and loss of scattering intensity was not observed (Table II).
Moreover, the reducing conditions did not signiﬁcantly
change the mean particle size, indicating that the assembled
structures were not affected by reduction of disulﬁde bonds.
In order to assess whether this disulﬁde bond formation
indeed stabilized the peptide assemblies, the organic solvent
DMF was added to the peptide dispersion to a ﬁnal
concentration of 95% (v/v). This solvent disrupts hydrogen
bonds as well as hydrophobic clustering effects and was found
a good solvent for hydrophobic or amphiphilic (poly)peptides
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subsequently injected into DMF, the particle light scattering
dropped to background levels instantaneously (Table II),
indicating full disintegration of the assembled structures. In
contrast, when the oxidized peptide assemblies were brought
into DMF, the scattering intensity remained and was stable
over time (Table II). DLS analysis on the assembled
structures in DMF indicated a mean particle radius of 50–
65 nm. Besides direct effects, noncovalent interparticle
interactions may be broken by DMF as well, which may
explain the observed lower mean particle radius. In conclu-
sion, the stability of the oxidized peptide assemblies in DMF
demonstrated that inter-peptide disulﬁde bonds were formed,
which covalently crosslinked the peptide assemblies.
The particle size derived from DLS measurements was
more closely examined. In Fig. 2, the particle size distribution
of SA2C2 and SA2C3 assemblies was plotted as a function of
the scattering intensity. The peptide assemblies displayed a
wide distribution of particle sizes. The peak around 100 nm,
which was the dominant peak, conﬁrms the mean particle
radii of Table II. Besides the 100 nm particles, light scattering
by smaller particles (peak around 10 nm, radius) was detected
as well for the oxidized SA2C2 and SA2C3 peptide disper-
sions (Fig. 2a and b). Since the size distribution graphs are
based on the scattering intensity, in number the smaller
particles may constitute the major fraction of the peptide
structures. In Fig. 2b also an ~2,000 nm peak was observed,
which was not present for the SA2C2 dispersion. The
2,000 nm peak diminished when the oxidized assemblies were
brought in DMF (Supplementary Information), which may
indicate some clustering of particles in aqueous environment.
The ~10 nm (radius) peak remained in DMF for both peptide
assemblies.
Cryogenic Electron Microscopy Analysis of Peptide
Assemblies
As DLS cannot reveal anything about the morphology of
the peptide assemblies, cryogenic transmission electron
microscopy (cryoTEM) was performed. The vitriﬁcation of
the sample in cryoTEM allowed the direct examination of the
peptide structures as present in solution. Representative
micrographs of the crosslinked peptide assemblies are shown
in Fig. 3. As can be seen in the micrographs, both SA2C2 and
SA2C3 samples (oxidized) showed spherical structures simi-
lar to what we have previously observed for SA2 peptides,
which formed vesicles (10). The size of the particles was
examined by measuring the diameter of 100 particles on
average at random tracks. Table III shows that the mean
particle radii for both the SA2C2 and SA2C3 assemblies was
<20 nm, which is substantially smaller than the size detected
by DLS (75 nm or larger; Table II). Some assemblies indeed
were clustered, which may in part explain the larger average
sizes detected with DLS (Fig. 2).
Table I. Synthesized Peptides
Peptide Sequence
SA2C2 Ac-Ala-Cys-Val-Cys-Leu-Leu-Leu-
Trp-Glu-Glu-COOH
SA2C3 Ac-Ala-Cys-Val-Cys-Leu-Cys-Leu-
Trp-Glu-Glu-COOH
SA2 Ac-Ala-Ala-Val-Val-Leu-Leu-Leu-
Trp-Glu-Glu-COOH
72
34
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B
24
35
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54
15
1   2   3    4 5 1 2 3 4 5
Reducing
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34
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A Non-reducing
24
35
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Fig. 1. SDS-PAGE analysis on the puriﬁed fusion proteins. Reducing
conditions (A): lane 1 SUMO-SA2C2, lane 2 SUMO-SA2C3, lane 3
molecular weight markers, lane 4 SUMO-SA2C2 partially cleaved, lane
5 SA2C3 partially cleaved. Non-reducing conditions (B) :l a n e1t h e
molecularweightmarker,lane2SUMO-SA2C2cleavedandnotcleaved
(lane 3), lane 4 SUMO-SA2C3 cleaved and not cleaved (lane 5).
Table II. DLS Analysis of the Peptide Assemblies with and without
Disulﬁde Bonds in Different Solvents
Solvent Radius (nm)
Mean count
rate (kcps)
SA2 PB 63 (±1) 380
DMF – 11
SA2C2, reduced PB, DTT 102 (±3) 340
DMF – 10
SA2C2, oxidized PB 106 (±2) 185
DMF 50 (±1) 200
SA2C3, reduced PB, DTT 69 (±8) 355
DMF – 10
SA2C3, oxidized PB 75 (±5) 280
DMF 63 (±1) 510
Radius (nm) Radius (nm)
0.1 10 100 1E3 1E4 0.1 10 100 1E3 1E4
0
0.2
0.4
0.6
0.8
1.0
1.2
A
0
0.4
0.2
0.6
0.8
1.0
1.2
B
11
Fig. 2. Dynamic light scattering size distribution graphs of the
oxidized SA2C2 (A) and SA2C3 (B) peptide assemblies in
10 mM PB of pH 8.0.
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Atomic Force Microscopy (AFM) was used to further
characterize particle morphology and size distribution of the
SA2C2 and SA2C3 peptide assemblies. After coating of the
mica with polyornithine (10), the negatively charged peptide
assemblies were immobilized on the surface, and AFM was
performed in solution. Fig. 4 shows representative AFM
micrographs of the crosslinked peptide assemblies. In accor-
dance with the cryoTEM, only spherical particles were
observed with AFM. The particle size and size distribution
were analyzed using AFM WSXM analysis software (19). As
can be seen in Table III, the average particle sizes derived
from the AFM measurements are in good agreement with the
average sizes found by cryoTEM. The mean particle radius
from either technique is ~20 nm for the SA2C3 assemblies,
and around 16 nm for the SA2C2, respectively. When the
A
B
Fig. 3. Cryogenic transmission electron microscopy micrographs of
the crosslinked SA2C2 (A) and SA2C3 (B) peptide assemblies.
Table III. Radii of Stabilized Oligopeptide Assemblies Based on Microscopic Analyses
Particle radius (nm)
SA2C2 SA2C3
Mean (stdev) Min Max Mean (stdev) Min Max
CryoTEM 14 (4) 7 56 19 (7)8 3 8
AFM 17 (7) 7 48 21 (8)8 5 1
A
B
Fig. 4. Atomic force microscopy of SA2C2 (A) and SA2C3 (B)
crosslinked assemblies immobilized on poly(ornithine) coated mica.
The scan size of the images is 1.0×1.0 μm and the z-scale is 16 nm.
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signiﬁcant difference in particle size nor in morphology were
observed as compared to the crosslinked peptide assemblies
(Supplementary Information). Contrary to non-crosslinked
particles, contact with the AFM-tip did not damage the
crosslinked assembled structures and instead could move the
spheres intact over the mica (results not shown). These
ﬁndings indicate that the intermolecular disulﬁde crosslinks
indeed preserved the peptide supramolecular structure,
making them more resistant to external disruptive forces.
Microscopy-Based Size Distribution
Using the data on particle size obtained with cryoTEM
and AFM, a microscopy-based size distribution graph was
constructed (Fig. 5). In agreement with DLS (Fig. 2), the
peptide assemblies displayed a wide particle size distribution.
The mean particle size as was determined by DLS, the
technique that is often used to establish the particle size and
size distribution (20,21), matched the largest particles present
in the particle population. This is explained by the fact that
this technique is exceptionally sensitive to the larger particles
in a population or a cluster of particles (scattering varies with
the 6
th power of the radius of the particles) (Fig. 2)( 22). The
actual size of the particles is relevant to, for example, drug
delivery applications. With respect to in vivo biodistribution
kinetics, reduction of the particle size typically correlates to
an enhanced penetration in diseased tissue, like tumors (23–
25). Moreover, small particle sizes may facilitate the cellular
entry of the drug carriers by endocytotic processes (26,27).
Based on the microscopic examination it can be concluded
that in number the majority (>90%) of the crosslinked
oligopeptide assemblies exhibited a radius between 7 and
30 nm for the SA2C2 assemblies, and between 10 and 30 nm
for SA2C3 assemblies.
Calcein Encapsulation and Release
We have previously shown that non-crosslinked SA2
peptide vesicles can be loaded with calcein (10). In order to
conﬁrm that the introduction of cysteine residues in the
peptide sequence does not harm self-assembly and the
vesicular architecture of these oligopeptides calcein entrap-
ment assay was performed for the SA2C2 and SA2C3
assemblies. Calcein was entrapped by hydration of the acid-
precipitated peptides in a buffered calcein solution (pH 8.0).
Separation of the free calcein from the calcein associated with
the peptide assemblies was done on a SEC spin column (15).
Eluted fractions were collected and screened for presence of
calceine ﬂuorescence. The peptide assemblies, eluting in the
void volume of the column, entrapped small but measurable
amounts of calcein (Fig. 6a). As a control, calcein was added
to empty pre-formed peptide vesicles before separation on
the column, resulting in minimal calcein co-elution (Fig. 6a).
This shows that co-elution of calcein with peptide vesicles is
not merely due to association of calcein with the peptide
vesicles. In agreement with the observed size distribution of
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Fig. 5. Size distributions in number of the SA2C2 (A) and SA2C3
(B) crosslinked assemblies, based on cryoTEM and AFM analysis.
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Fig. 6. Calcein encapsulation (A) and release (B) from the peptide
assemblies. A. Crosslinked SA2C2 (triangles) and SA2C3 (blocks)
assemblies prepared in the presence of calcein were separated on a
size exclusion spin column. Fraction 1 and 2 represented the void
volume containing the peptide assemblies. When calcein was added
to preformed assembled peptide (control) no calcein elution in the
void volume was observed. B. Release of calcein from the crosslinked
SA2C2 (diamonds) SA2C3 (open blocks) and the non-crosslinked
SA2 (filled blocks) peptide assemblies.
2191 Crosslinkable Oligopeptide Vesiclesthe assemblies (Fig. 5), the calcein entrapment data conﬁrm
the vesicular architecture. Indeed, similar surfactant-like
peptides but with a different primary sequence also were
demonstrated to form stable assemblies with a hydrophilic
interior of radii comparable to the SA2C2 and SA2C3
assemblies (28,29).
We next tested whether inter-peptide disulﬁde cross-
linking would change the release kinetics of calcein from
these peptide vesicles. As a vesicular assembly the oligopep-
tides constitute a barrier towards release of small hydrophilic
molecules. By covalent crosslinking this barrier function may
be increased or remain unaffected, or may have decreased
and become more permeable. For this, self-quenched con-
centrations of calcein were entrapped inside non-crosslinked
and crosslinked peptide vesicles after which calcein release
was monitored under sink conditions. As is shown in Fig. 6b,
the release of calcein from both the SA2C2 and SA2C3
peptide vesicles showed an initial fast rate, with 50% of
calcein released in 24 h, followed by a much slower release
rate that continued for days. No signiﬁcant differences were
observed between the peptides containing 2 or 3 cysteines.
Interestingly, the release of calcein from the crosslinked
peptide assemblies was comparable to the non-crosslinked
SA2 peptides, indicating that the covalent bonds between the
peptide monomers did not increase the barrier function of
oligopeptides towards small hydrophilic molecules like cal-
cein. Evidently, the diffusion is limited if larger molecules are
entrapped in the crosslinked oligopeptide vesicles and
ﬂuorescently labeled dextran 10,000, for example, diffused
poorly after entrapment in the SA2C3 vesicles, over 24 h only
releasing 12% of the total entrapped amount (see Supple-
mentary information).
CONCLUSION
Although various strategies for the covalent stabilization
of supramolecular assemblies have been exploited (16),
disulﬁde bond formation as presented here is an attractive
route for crosslinking self-assembled peptide vesicles. We
showed that disulﬁde crosslinking of peptide vesicles resulted
in vesicles that remained intact under conditions that
disrupted non-crosslinked vesicles and liposomes. Interesting-
ly, peptide vesicle crosslinking did not have an effect on the
release kinetics of calcein, indicating that calcein release is
not dependent on the exchange of peptide monomers from
vesicular assemblies but driven by other as yet unclear
mechanisms. The rate of calcein release from peptide vesicles
as shown here is much faster compared to calcein release
from liposomes. This may be explained by differences in the
hydrophobic domains of liposomes compared to peptides
vesicles, with the latter being able to form hydrogen-bonds
with water or entrapped substrates, thereby facilitating
transport of small, hydrophilic compounds over the peptide
membrane. This high permeability of small substrates may be
an advantage for particular drug delivery applications. For
example, peptide vesicles may be ideal for delivering
potentially immunogenic prodrug-converting enzymes to
tumor sites without the need to artiﬁcially enhance mem-
brane permeability as has been described for liposomes (30).
In vitro evaluation of peptide vesicles as drug delivery
systems is currently under way.
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